Nitric oxide inhibits proliferation of human endothelial cells via a mechanism independent of cGMP

Atherosclerosis

Volumn 144, Issue 1, 1999, Pages 49-57

  Heller, R ^a   Polack, T ^a   Grabner R ^a   Till, U ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Endothelium; Guanylate cyclase; Nitric oxide; Proliferation

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; CYCLIC GMP; DNA; GUANYLATE CYCLASE; N ACETYL S NITROSOPENICILLAMINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PEROXYNITRITE; S NITROSOGLUTATHIONE; SUPEROXIDE DISMUTASE; THROMBIN; THYMIDINE; TRITIUM;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY; ENDOTHELIUM CELL; EPITHELIUM HYPERPLASIA; GROWTH INHIBITION; HUMAN; HUMAN CELL; INTIMA; PRIORITY JOURNAL; UMBILICAL VEIN;

ANALYSIS OF VARIANCE; CELL DIVISION; CELLS, CULTURED; CORONARY VESSELS; CYCLIC GMP; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; GUANYLATE CYCLASE; HALF-LIFE; HUMANS; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; THYMIDINE; UMBILICAL VEINS;

EID: 0032973685     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00041-6     Document Type: Article

References (42)

1. Furchgott RF, Zawadski JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-6.
2. Alheid U, Frölich JC, Förstermann U. Endothelium-derived relaxing factor from cultured human endothelial cells inhibits aggregation of human platelets. Thromb Res 1987;47:561-71.
3. Westendorp RGJ, Draijer R, Meinders AE, van Hinsberg VWM. Cyclic-GMP-mediated decrease in permeability of human umbilical and pulmonary artery endothelial cell monolayers. J Vase Res 1994;31:42-51.
4. Heller R, Bussolino F, Ghigo D, Pescarmona GP, Calvino R, Gasco A, Till U, Bosia A. Activation of endothelial guanylate cyclase inhibits cellular reactivity. Agents Actions 1994;45:17781.
5. Bull H. Nitric oxide and atherosclerosis: possible implications for therapy. Mol Med Today 1996;2:510-8.
6. Anderson TJ, Gerhard MD, Meredith IT, Charbonneau F, Delagrange D, Creager MA, Selwyn AP, Ganz P. Systemic nature of endothelial dysfunction in atherosclerosis. Am J Cardiol 1995;75:71B-4B.
7. Zeiher AM, Drexler H, Wollschläger H, Just HJ. Modulation of coronary vasomotor tone in humans: progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 1991;83:391-401.
8. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1774-7.
9. Dubey RK. Vasodilator-derived nitric oxide inhibits fetal calf serum- and angiotensin-II-induced growth of renal arteriolar smooth muscle cells. J Pharmacol Exp Ther 1994;269:402-8.
10. Kullo IJ, Schwartz RS, Pompili VJ, Tsutsui M, Milstien S, Fitzpatrick LA, Katusic ZS, O'Brien T. Expression and function of recombinant endothelial NO synthase in coronary artery smooth muscle cells. Arterioscler Thromb Vase Biol 1997;17:2405-12.
11. Kojda G, Noack E. Effects of pentaerythrityl-tetranitrate and isosorbide-5-mononitrate in experimental atherosclerosis. Agents Actions Suppl 1995;45:201-6.
12. von der Leyen HE, Gibbons GH, Morishita R, Lewis NP, Zhang L, Nakajima M, Kaneda Y, Cooke JP, Dzau VJ. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sei USA 1995;92:1137-41.
13. Yu S-M, Hung LM, Lin CC. cGMP-elevating agents suppress proliferation of vascular smooth muscle cells by inhibiting the activation of epidermal growth factor signaling pathway. Circulation 1997:95:1269-77.
14. Abell TJ, Richards AM, Ikram H, Espinier EA, Yandle T. Atrial natriuretic factor inhibits proliferation of vascular smooth muscle cells stimulated by platelet-derived growth factor. Biochem Biophys Res Commun 1989; 160:1392-6.
15. Garg U, Hassid A. Inhibition of rat mesangial cell mitogenesis by nitric oxide-generating vasodilators. Am J Physiol 1989;257:60F-6F.
16. Garg UC, Hassid A. Nitric oxide decreases cytosolic free calcium in Balb/c 3T3 fibroblasts by a cyclic GMP-independent mechanism. Biochem Biophys Res Commun 1990;171:474-9.
17. Denham S, Rowland IJ. Inhibition of the reactive proliferation of lymphocytes by activated macrophages: the role of nitric oxide. Clin Exp Immunol 1992;87:157-62.
18. Ziehe M, Morbidelli L, Masini E, Granger H, Geppetti P, Ledda F. Nitric oxide promotes DNA synthesis and cyclic GMP formation in endothelial cells from postcapillary venules. Biochem Biophys Res Commun 1993;192:1198-203.
19. Yang W, Ando J, Korenaga R, Toyo-oka T, Kamiya A. Exogenous nitric oxide inhibits proliferation of cultured vascular endothelial cells. Biochem Biophys Res Commun 1994;203:1160-7.
20. Arnal J-F, Yamin J, Dockery S, Harrison DG. Regulation of endothelial nitric oxide synthase mRNA, protein, and activity during cell growth. Am J Physiol 1994;267:C1381-8.
21. Papapetropoulos A, Desai KM, Rudic RD, Mayer B, Zhang R, Ruiz-Torres M, Garcia-Cardena G, Madri JA, Sessa WC. Nitric oxide synthase inhibitors attenuate transforming-growth-factorβ,-stimulated capillary organization in vitro. Am J Pathol 1997:150:1835-44.
22. Gooch KJ, Dangler CA, Frangos JA. Exogenous, basal, and flow-induced nitric oxide production and endothelial cell proliferation. J Cell Physiol 1997;171:252-8.
23. Sarkar R, Webb RC, Stanley JC. Nitric oxide inhibition of endothelial cell mitogenesis and proliferation. Surgery 1995:118:274-9.
24. Lopez-Farre A, Sanchez de Miguel L, Caramelo C, Gomez-Macias J, Garcia R, Mosquera JR, de Frutos T, Millas I, Rivas F, Echezarreta G, Casado S. Role of nitric oxide in autocrine control of growth and apoptosis of endothelial cells. Am J Physiol 1997;272:H760-8.
25. Ziehe M, Morbidelli L, Masini E, Amerini S, Granger HJ, Maggi CA, Geppetti P, Ledda F. Nitric oxide mediates angiogenesis in vivo and endothelial growth and migration in vitro promoted by substance P. J Clin Invest 1994;94:2036-44.
26. Kröncke K-D, Fehsei K, Kolb-Bachofen V. Inducible nitric oxide synthase and its product nitric oxide, a small molecule with complex biological activities. Biol Chem Hoppe-Seyler 1995;376:327-43.
27. Garthwaite J, Southam E, Boulton CL, Nielsen EB, Schmidt K, Mayer B. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by lH-[l,2,4]oxadiazolo[4,3,-α]quinoxalin-lone. Mol Pharmacol 1995;48:184-8.
28. Ormerod MG. Analysis of DNA-general methods. In: Ormerod MG, editor. Flow Cytometry. A Practical Approach. Oxford: IRL Press, 1994:119-35.
29. Ghigo D, Alessio P, Foco A, Bussolino F, Costamagna C, Heller R, Garbarino G, Pescarmona GP, Bosia A. Nitric oxide synthesis is impaired in glutathione-depleted human umbilical vein endothelial cells. Am J Physiol 1993;265:C728-32.
30. Lowry OH, Rosenbrough AL, Farr RJ, Randall RJ. Protein measurement with folin phenol reagent. J Biol Chem 1951;193:265-75.
31. Verbeuren TJ, Bonhomme E, Laubie M, Simonet S. Evidence for induction of nonendothelial NO synthase in aortas of cholesterol-fed rabbits. J Cardiovasc Pharmacol 1993;21:841-5.
32. Yan Z-Q, Yokota T, Zhang W, Hansson GK. Expression of inducible nitric oxide synthase inhibits platelet adhesion and restores blood flow in the injured artery. Circ Res 1996;79:3844.
33. Sobey CG, Brooks RM, Heistad DD. Evidence that expression of inducible nitric oxide synthase in response to endotoxin is augmented in atherosclerotic rabbits. Circ Res 1995;77:536-43.
34. Kreye VAW. Sodium nitroprusside. In: Scriabine A, editor. Pharmacology of Antihypertensive Drugs. New York: Raven Press, 1980:373-96.
35. Chasseaud LF, Down WH, Grundy RK. Concentrations of the vasodilator isosorbide dinitrate and its metabolites in the blood of human subjects. Eur J Clin Pharmacol 1975;8:157-60.
36. Abshagen UW. Pharmacokinetics of isosorbide mononitrate. Am J Cardiol 1992;70:61G-6G.
37. Morbidelli L, Chang C-H, Douglas JG, Granger HJ, Ledda F, Ziehe M. Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium. Am J Physiol 1996;270:H411-5.
38. Okamura T, Yoshida K, Toda N. Suppression by méthyléne blue of prostaglandin I2 synthesis in isolated dog renal arteries. J Pharmacol Exp Ther 1990;254:198-203.
39. Wolin MS, Cherry PD, Rodenburg JM, Messina EJ, Kaley G. Méthyléne blue inhibits vasodilation of skeletal muscle arterioles to acetylcholine and nitric oxide via the extracellular generation of superoxide anion. J Pharmacol Exp Ther 1990;254:872-6.
40. Mayer B, Brunner F, Schmidt K. Inhibition of nitric oxide synthesis by méthyléne blue. Biochem Pharmacol 1993;45:36774.
41. Kwon NS, Stuehr DJ, Nathan CF. Inhibition of tumor cell ribonucleotide reductase by macrophage-derived nitric oxide. J Exp Med 1991:174:761-7.
42. Lepoivre M, Flaman J-M, Henry Y. Early loss of the tyrosyl radical in ribonucleotide reductase of adenocarcinoma cells producing nitric oxide. J Biol Chem 1992;267:22994-3000.